ProfileGDS5678 / 1418979_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 66% 89% 68% 73% 66% 61% 76% 76% 65% 62% 70% 67% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.11167
GSM967853U87-EV human glioblastoma xenograft - Control 24.0183166
GSM967854U87-EV human glioblastoma xenograft - Control 37.0991589
GSM967855U87-EV human glioblastoma xenograft - Control 44.2104868
GSM967856U87-EV human glioblastoma xenograft - Control 54.643973
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0206866
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.72661
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.131176
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0665276
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9162165
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6792862
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4003170
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0623767
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6783862